GH1 and central nervous system neoplasm: After a cranial radiation therapy induced GH deficiency (GHD), 4.7% GH-treated survivors developed subsequent neoplasms of the central nervous system, while only 1.7% developed without GH treatment (Patterson et al., 2014).